Bilobetin has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 15, 2026: “Bilobetin eased infection-driven immune aging in mice”.
1 new paper in 30 daysSee all 1 papers on bilobetin
The findings reach mice, none yet in people. 1 lab.
None of its findings points the other way.
Studies of bilobetin measured 3 outcomes: hematopoietic stem cell aging and systemic immunosenescence, MAVS signaling and mitochondrial fitness.
Hematopoietic stem cell aging and systemic immunosenescence
downin mice1
Bilobetin decreases hematopoietic stem cell aging and systemic immunosenescence in mice (influenza A virus infection model).
“Bilobetin, a natural biflavonoid, as a potent mitochondria-targeted compound that restores mitochondrial fitness, dampens aberrant MAVS signaling, and ameliorates both HSC aging and systemic immunosenescence.”
Animalsinfluenza A virus infection model
Bilobetin eased infection-driven immune aging in mice
Aging and disease
MAVS signaling
downin mice1
Bilobetin inhibits MAVS signaling in mice (influenza A virus infection model).
“Bilobetin, a natural biflavonoid, as a potent mitochondria-targeted compound that restores mitochondrial fitness, dampens aberrant MAVS signaling”
Animalsinfluenza A virus infection model
Bilobetin eased infection-driven immune aging in mice
Aging and disease
Mitochondrial fitness
upin mice1
Bilobetin improves mitochondrial fitness in mice (influenza A virus infection model).
“Bilobetin, a natural biflavonoid, as a potent mitochondria-targeted compound that restores mitochondrial fitness”
Animalsinfluenza A virus infection model
Bilobetin eased infection-driven immune aging in mice
Aging and disease
In experiments with nonlethal influenza infection, middle-aged mice—but not young mice—were susceptible to lasting immune deterioration.In experiments with nonlethal influenza infection, middle-aged mice—but not young mice—were susceptible to lasting immune deterioration.